Profound Medical Corp. (PROF)
Automate Your Wheel Strategy on PROF
With Tiblio's Option Bot, you can configure your own wheel strategy including PROF - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PROF
- Rev/Share 0.5112
- Book/Share 1.0677
- PB 6.0128
- Debt/Equity 0.0086
- CurrentRatio 4.1783
- ROIC -3.5515
- MktCap 193842861.0
- FreeCF/Share -1.2448
- PFCF -5.1727
- PE -4.6043
- Debt/Assets 0.0065
- DivYield 0
- ROE -0.9195
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
Published: March 17, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ: PROF). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Profound Medical Being Investigated on Behalf of Profound Medical Corp. Investors. Contact Levi & Korsinsky For Details
Published: March 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Profound Medical Corp. ("Profound Medical") (NASDAQ:PROF) concerning possible violations of federal securities laws. Profound disclosed in a filing with the U.S. Securities and Exchange Commission on March 7, 2025, that "the Company identified an error which overstated revenue by $472,000 in the first quarter of 2024.
Read More
Profound Medical Stock Alert: Company Reports Error which Overstated Revenue - Kehoe Law Firm, P.C. Investigating - PROF
Published: March 13, 2025 by: Accesswire
Sentiment: Neutral
PHILADELPHIA, PA / ACCESS Newswire / March 13, 2025 / Kehoe Law Firm, P.C. is investigating potential securities fraud claims on behalf of investors of Profound Medical Corp. ("Profound Medical," "Profound," or the "Company") (NASDAQ:PROF).
Read More
Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025.
Read More
About Profound Medical Corp. (PROF)
- IPO Date 2019-10-29
- Website https://www.profoundmedical.com
- Industry Medical - Devices
- CEO Arun Swarup Menawat MBA,
- Employees 142